liver

Bio & Pharma S.Korea’s GC Cell targets global cell therapy CDMO business

GC Cell Corp., an affiliate of South Korea’s major pharmaceutical company GC Biopharma Corp., is targeting the cell therapy contract developme...

Bio & Pharma HLB gets global rights to Chinese liver cancer drug

South Korea’s HLB Therapeutics Co. on Tuesday said its US subsidiary Elevar Therapeutics has acquired the global rights excluding South Kore...

Bio & Pharma VaxCell Bio's treatment shows promise for advanced liver cancer

South Korea's VaxCell Biotherapeutics Co. on Tuesday said its treatment for advanced liver cancer under development stopped or greatly reduced the g...

Bio & Pharma S.Korea's T&R Biofab secures patent in Japan for 3D-printed liver

South Korea's regenerative medicine company T&R Biofab Co. on Monday said it obtained a patent in Japan for production technology for liver or...

Bio & Pharma HLB submits new drug application to FDA for Rivoceranib liver cancer drug

HLB Co. announced on May 17 that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Rivo...

Bio & Pharma Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer

South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...